Defining Progression in Metastatic Kidney Cancer
3 Pogledi
• 06/26/23
0
0
Ugraditi
administrator
Pretplatnici
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari